A detailed history of Engineers Gate Manager LP transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Engineers Gate Manager LP holds 5,581 shares of XENE stock, worth $214,422. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,581
Previous 29,293 80.95%
Holding current value
$214,422
Previous $1.14 Million 80.82%
% of portfolio
0.0%
Previous 0.03%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$36.12 - $43.96 $856,477 - $1.04 Million
-23,712 Reduced 80.95%
5,581 $219,000
Q2 2024

Aug 14, 2024

BUY
$36.25 - $43.75 $100,775 - $121,625
2,780 Added 10.49%
29,293 $1.14 Million
Q1 2024

May 15, 2024

BUY
$42.66 - $50.04 $1.13 Million - $1.33 Million
26,513 New
26,513 $1.14 Million
Q4 2022

Feb 14, 2023

BUY
$33.06 - $39.43 $154,257 - $183,980
4,666 Added 48.02%
14,383 $567,000
Q3 2022

Nov 14, 2022

SELL
$30.79 - $39.82 $401,193 - $518,854
-13,030 Reduced 57.28%
9,717 $351,000
Q2 2022

Aug 15, 2022

SELL
$25.44 - $35.16 $255,875 - $353,639
-10,058 Reduced 30.66%
22,747 $692,000
Q1 2022

May 16, 2022

BUY
$25.09 - $33.13 $595,184 - $785,909
23,722 Added 261.17%
32,805 $1 Million
Q4 2021

Feb 14, 2022

SELL
$15.6 - $35.4 $79,045 - $179,371
-5,067 Reduced 35.81%
9,083 $284,000
Q3 2021

Nov 15, 2021

BUY
$14.86 - $19.45 $210,269 - $275,217
14,150 New
14,150 $216,000
Q2 2021

Aug 16, 2021

SELL
$16.81 - $20.0 $190,457 - $226,600
-11,330 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$13.65 - $21.31 $154,654 - $241,442
11,330 New
11,330 $203,000
Q2 2020

Aug 17, 2020

SELL
$10.21 - $14.9 $166,280 - $242,661
-16,286 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$8.08 - $17.57 $131,590 - $286,145
16,286 New
16,286 $185,000

Others Institutions Holding XENE

About Xenon Pharmaceuticals Inc.


  • Ticker XENE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,263,500
  • Market Cap $2.39B
  • Description
  • Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...
More about XENE
Track This Portfolio

Track Engineers Gate Manager LP Portfolio

Follow Engineers Gate Manager LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

News

Stay updated on Engineers Gate Manager LP with notifications on news.